Alnylam Pharmaceuticals Inc banner

Alnylam Pharmaceuticals Inc
LSE:0HD2

Watchlist Manager
Alnylam Pharmaceuticals Inc Logo
Alnylam Pharmaceuticals Inc
LSE:0HD2
Watchlist
Price: 296.43 USD 0.24% Market Closed
Market Cap: $39.2B

Wall St Price Targets

0HD2 Price Targets Summary
Alnylam Pharmaceuticals Inc

Wall Street analysts forecast 0HD2 stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for 0HD2 is 446.53 USD with a low forecast of 234.11 USD and a high forecast of 583.71 USD.

Lowest Forecast
Price Target
234.11 USD
21% Downside
Average Forecast
Price Target
446.53 USD
51% Upside
Highest Forecast
Price Target
583.71 USD
97% Upside
Alnylam Pharmaceuticals Inc Competitors:
Price Targets
RLMD
Relmada Therapeutics Inc
92% Upside
AMSF
Amerisafe Inc
26% Upside
PGEN
Precigen Inc
130% Upside

Revenue
Forecast

36% / Year
Past Growth
17% / Year
Estimated Growth
Estimates Accuracy
0%
Average Beat
36% / Year
Past Growth
17% / Year
Estimated Growth
Estimates Accuracy
0%
Average Beat

Over the last 13 years, the compound annual growth rate for Revenue has been 36%. The projected CAGR for the next 8 years is 17%.

Operating Income
Forecast

N/A
Past Growth
36% / Year
Estimated Growth
Estimates Accuracy
2%
Average Beat
N/A
Past Growth
36% / Year
Estimated Growth
Estimates Accuracy
2%
Average Beat

The compound annual growth rate for Operating Income over the next 8 years is 36%.

Net Income
Forecast

N/A
Past Growth
41% / Year
Estimated Growth
Estimates Accuracy
-21%
Average Miss
N/A
Past Growth
41% / Year
Estimated Growth
Estimates Accuracy
-21%
Average Miss

The compound annual growth rate for Net Income over the next 8 years is 41%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is 0HD2's stock price target?
Price Target
446.53 USD

According to Wall Street analysts, the average 1-year price target for 0HD2 is 446.53 USD with a low forecast of 234.11 USD and a high forecast of 583.71 USD.

What is the Revenue forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
17%

Over the last 13 years, the compound annual growth rate for Revenue has been 36%. The projected CAGR for the next 8 years is 17%.

What is the Operating Income forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
36%

The compound annual growth rate for Operating Income over the next 8 years is 36%.

What is the Net Income forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
41%

The compound annual growth rate for Net Income over the next 8 years is 41%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett